Drugs / NLIR+FU/FA
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04037241 Background | Nov 2021 → Jan 2022 | malignant pancreatic neoplasm | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NLIR+FU/FA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04037241 ↗ |
| Known as | NLIR | “Patients in the "anti-CEA CAR-T Cells plus and nanolipsomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA)" will have achieved at least stable disease during the...” NCT04037241 ↗ |